Clarient, Inc Watch

from 10-Q 11 pages 2. Term. Notwithstanding Anything to the Contrary, Executive’s Employment Relationship With the Company Is Employment “At Will”. as a Result, Executive’s Employment May Be Terminated by the Company or by Executive at Any Time (Subject to the Notice Provision Below), in Each Case Without Any Liability or Obligation, Except as Set Forth in This Letter Agreement. if Executive Terminates His Employment, He Shall Give the Company Written Notice of Such Termination Not Less Than Thirty (30) Days Prior to the Effective Date of Such Termination. in Light of the Severance Benefits Provided for in Section 6, the Company Will Have No Obligation to Give Executive Prior Notice of Any Such Termination by the Company (Whether or Not Such Termination Is Without Cause). 3. Compensation. (A) Base Salary. During the Term of Executive’s Employment, Executive Will Receive a Base Salary of $256,500 Per Annum, Payable in Biweekly Increments, Subject to Annual Salary and Performance Review and Potential Salary Increase (But Not Reductions) at the Sole Discretion of the Company

from 10-Q 11 pages 2. Term. Notwithstanding Anything to the Contrary, Executive’s Employment Relationship With the Company Is Employment “At Will”. as a Result, Executive’s Employment May Be Terminated by the Company or by Executive at Any Time (Subject to the Notice Provision Below), in Each Case Without Any Liability or Obligation, Except as Set Forth in This Letter Agreement. if Executive Terminates His Employment, He Shall Give the Company Written Notice of Such Termination Not Less Than Thirty (30) Days Prior to the Effective Date of Such Termination. in Light of the Severance Benefits Provided for in Section 6, the Company Will Have No Obligation to Give Executive Prior Notice of Any Such Termination by the Company (Whether or Not Such Termination Is Without Cause). 3. Compensation. A. Base Salary. During the Term of Executive’s Employment, Executive Will Receive a Base Salary of $347,500 Per Annum, Payable in Biweekly Increments, Subject to Annual Salary and Performance Review and Potential Salary Increase (But Not Reductions) at the Sole Discretion of the Company

from 10-Q 11 pages 2. Term. Notwithstanding Anything to the Contrary, Executive’s Employment Relationship With the Company Is Employment “At Will”. as a Result, Executive’s Employment May Be Terminated by the Company or by Executive at Any Time (Subject to the Notice Provision Below), in Each Case Without Any Liability or Obligation, Except as Set Forth in This Letter Agreement. if Executive Terminates His Employment, He Shall Give the Company Written Notice of Such Termination Not Less Than Thirty (30) Days Prior to the Effective Date of Such Termination. in Light of the Severance Benefits Provided for in Section 6, the Company Will Have No Obligation to Give Executive Prior Notice of Any Such Termination by the Company (Whether or Not Such Termination Is Without Cause). 3. Compensation. (A) Base Salary. During the Term of Executive’s Employment, Executive Will Receive a Base Salary of $450,000 Per Annum, Payable in Biweekly Increments, Subject to Annual Salary and Performance Review and Potential Salary Increase (But Not Reductions) at the Sole Discretion of the Company

from 8-K 11 pages Oak Investment Partners XII, Limited Partnership October 22, 2010

from 8-K 11 pages Safeguard Scientifics, Inc. October 22, 2010

from 8-K 13 pages Tender and Support Agreement

from 8-K 13 pages Tender and Support Agreement

from 8-K 17 pages Clarient, Inc. 2007 Incentive Award Plan as Amended by Resolution Adopted by the Board of Directors on April 14, 2010, and Approved by Stockholders on June 8, 2010 Article 1 Purpose

from 8-K 3 pages Clarient, Inc. Amendment No. 1 to Agreement and Plan of Merger

from 10-K 1 page 2009 Management Incentive Plan

from 10-K 35 pages Lease Agreement Between Hudson-Alpha Institute for Biotechnology and Applied Genomics, Inc. Suite No. 2200

from 10-K 5 pages First Amendment to Lease Agreement

from 10-K 9 pages Separation Agreement and Waiver and Release of All Claims

from 8-K 9 pages Mr. Michael R. Rodriguez [Address Redacted] December 2, 2009 Dear Michael

from 10-Q 5 pages Confidential Portions Have Been Omitted Based Upon a Request for Confidential Treatment Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 and Have Been Separately Filed With the Securities and Exchange Commission. Amendment to License Agreement Between Prediction Sciences, LLC. and Clarient, Inc

from 10-Q 30 pages Confidential Portions Have Been Omitted Based Upon a Request for Confidential Treatment Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 and Have Been Separately Filed With the Securities and Exchange Commission. License Agreement

from 8-K 9 pages 1. Duties. Executive Shall Continue to Serve as the Chief Medical Officer of Clarient and Shall Report to Clarient’s Chief Executive Officer. Executive Shall Be Responsible for the Technical Oversight and Management of the Diagnostics Services Laboratory Operated by Clarient and Clarient Diagnostics Services, Inc., a Delaware Corporation and Wholly Owned Subsidiary of Clarient (“Cds”), and Shall Have Such Other Duties and Responsibilities as Are Consistent With Executive’s Position and as May Be Requested From Time to Time by the Chief Executive Officer of Clarient. Executive Will Receive Compensation From Clarient for Executive’s Employment Hereunder as Set Forth in Section 3 Below. Notwithstanding Any of the Foregoing, Executive Shall Not Be Required to Provide, Nor Shall He Provide, Any Professional Pathology or Other Medical Services to Clarient or Cds in His Capacity as Chief Medical Officer of Clarient, Nor Shall Clarient Bill Any Third Parties (Including Medicare and Private Health Insurers), Clients or Patients for Any Services Provided by Executive in His Capacity as Chief Medical Officer to Clarient or Cds Hereunder, and Under No Circumstances Shall Clarient Compensate Executive for Any Professional Pathology or Other Medical Services Performed by Executive in His Capacity as President of Clarient Pathology Services, Inc., a California Professional Corporation (“Cps”). This Letter Agreement Amends, Restates and Supersedes in Its Entirety the Employment Letter Agreement, Dated as of December 15, 2008, by and Among Clarient, Cps and Executive

from 8-K 20 pages Amended and Restated Professional Services Agreement by and Between Clarient Diagnostic Services, Inc., Clarient, Inc. and Clarient Pathology Services, Inc. Amended and Restated Professional Services Agreement

from 8-K/A 83 pages Stock Purchase Agreement by and Among Clarient, Inc. and Oak Investment Partners XII, Limited Partnership March 25, 2009

from 8-K 17 pages Clarient, Inc. 2007 Incentive Award Plan (As Amended) Article 1 Purpose